+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05775458

Study of Glutamates Role in Growth and Spread of Glioblastoma Brain Tumors in Adults Undergoing Surgery and Treatment

Led by IRCCS San Raffaele · Updated on 2025-06-11

50

Participants Needed

1

Research Sites

47 weeks

Total Duration

AI-Summary

What this Trial Is About

Gliomas are the most common primary brain tumors in adults, with glioblastoma multiforme GBM being the most aggressive and associated with the poorest outcomes. Researchers are studying the role of glutamate, an amino acid important for brain function, in GBM growth and invasion. Alterations in glutamate synthesis and signaling may influence tumor aggressiveness, making it a focus for potential new treatments. The study involves measuring levels of glutamate and related proteins in blood, cerebrospinal fluid CSF, and tumor tissue from adult patients with brain lesions suspected to be GBM. These patients are candidates for complete tumor removal surgery followed by radiotherapy and chemotherapy. Samples will be collected at baseline before surgery and during follow-up visits at 3, 6, and 9 months. Molecular analyses and imaging, including MRI scans, will also be performed. Participants will undergo regular blood sampling and MRI scans at specified intervals to monitor glutamate levels and tumor progression. Researchers will assess changes in glutamate and its scavengers in serum and CSF over time to understand their relationship with disease activity. The study includes collection of clinical and imaging data throughout the follow-up period, with the total observation lasting at least 9 months after surgery.

CONDITIONS

Brief Title

Glutamate Excitotoxicity and Its Role in Glioblastoma Biology

Research Team

S

Sincinelli Laura

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here